Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis

PURPOSE: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, key drivers of chronic inflammation. Bimekizumab must be injected subcutaneously and so patients require self-injection options that meet their preferences. This study evaluated s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan, Ellis, Alicia M, Shende, Vishvesh, Lambert, Jérémy, Tatla, Daljit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559892/
https://www.ncbi.nlm.nih.gov/pubmed/37808274
http://dx.doi.org/10.2147/PPA.S427809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559892/
https://www.ncbi.nlm.nih.gov/pubmed/37808274
http://dx.doi.org/10.2147/PPA.S427809

Ejemplares similares